Last updated: 2026-09-06 13:48:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Liquidia Corporation (LQDA) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $68.68, with a market capitalization of $6.15B and a P/E ratio of 44.34. Over the past 52 weeks, its price has ranged from $21.15 to $93.61. This page covers its latest market performance, valuation, price trends and company information.
$6.15B | |
$67.91 | |
$93.61 | |
$2.25 | |
$68.63 | |
689.17K | |
1.82M | |
44.34 | |
$93.61 | |
$21.15 | |
-- | |
-- |
Liquidia Corporation (LQDA) last closed at $68.63 as of 2026-09-04 23:43:00, unchanged from the previous close of $68.63.
During the latest regular trading session, LQDA traded between $2.25 and $93.61, with a volume of 689.17K shares. The closing price was near the upper end and near the middle of its 52-week range.
Over the past seven days, Liquidia Corporation (LQDA) moved from $69.94 to $68.68, representing a decline of 1.80% ($1.26).
The stock traded between $66.10 and $71.70 during the period. The latest price is near the middle of the 7-day range, indicating moderate downward.
The average daily volume was 1.01 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 65.6%
LQDA is currently trading at $68.68, placing it 65.6% of the way from its 52-week low of $21.15 to its 52-week high of $93.61. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 216 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Liquidia Corporation (LQDA) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.